PNC-27 – 30mg

PNC-27

This product is not intended for weight loss, human consumption, or veterinary use. It is sold for research purposes only. Please handle with care and follow all safety guidelines for the specific chemicals involved.

PNC-27 is a 32-residue, p53-derived chimeric peptide that selectively kills cancer cells by binding membrane-associated HDM-2 (MDM2) and promoting the formation of transmembrane pores that cause rapid necrosis. Researchers looking to buy PNC-27 peptide for laboratory studies will find this compound valuable for investigating membrane-targeting mechanisms. Structural and cell-biological work showed the p53-derived segment of PNC-27 peptide adopts a conformation compatible with the HDM-2 p53-binding pocket and colocalizes with HDM-2 in cancer cell membranes — an interaction that precedes membrane lysis. (PubMed)

When investigators examined rat-derived experimental systems, they frequently used rat pancreatic tumor cell lines such as TUC-3 and BMRPA1 (ras-transformed acinar cells) to probe mechanisms and susceptibility. In vitro, these rat tumor cells express membrane HDM-2 and are susceptible to peptide-induced membranolysis, mirroring results in human cancer cell lines and supporting the idea that membrane HDM-2 expression determines sensitivity. (PubMed)

In vivo work with closely related PNC peptides (for example, PNC-28) has shown that intraperitoneal or local administration can markedly reduce the growth of implanted tumors in rodent xenograft models — experiments that used mouse hosts bearing rat-derived tumor grafts (BMRPA1/TUC-3) and demonstrated pronounced antitumor effects with limited damage to surrounding normal tissues. These in vivo results support the translational potential of membrane-targeting peptides, although many published efficacy studies used mice as the host species rather than systemic dosing in rats. (PubMed)

A recent review summarizes these and newer data, describing “peptide-induced poptosis” (PNC-27/PNC-28 family) as a distinct, p53-independent route to cancer cell necrosis and noting continued preclinical development, including cell lines of rat origin and mechanistic imaging of mitochondrial involvement following peptide uptake. The review also emphasizes that most systemic safety and pharmacokinetic data remain limited and that further animal toxicology (including dedicated rat studies) is needed before clinical translation. (PubMed)

Selected PubMed references

1. Sarafraz-Yazdi E et al., Proc Natl Acad Sci U S A. 2010. PMID: 20080680. (PubMed)
2. Michl J et al., Int J Cancer. 2006 (PNC-28; rat BMRPA1/TUC-3 work). PMID: 16688716. (PubMed)
3. Pincus MR et al., Biomedicines. 2024 (review: peptide-induced poptosis). PMID: 38927351. (PubMed)